October 23, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Suprema Provides Palm-print Live Scanners to Poland & Lithuania
Seoul, Nov 23, 2010 - (ACN Newswire) - Suprema, Inc., a global leader in biometrics and ID solutions, announced today that the company's RealScan-F palm-print live scanner has been selected for the AFIS systems of the Polish National Police and Lithuania's Citizenship & Migration Affairs.   [ more... ]

 Headline News

Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Otsuka Pharmaceutical's QuickNavi(TM)-Flu, a rapid diagnostic test kit for the influenza virus, has the leading market share in Japan among products in this category. more info >>
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Nitto Denko Corporation (Nitto) announced the initiation of a phase-1b clinical study in the US started in September 2014, to administer a new anti-fibrosis drug in patients for the assessment of safety and efficacy. more info >>
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Mitsui & Co. has invested in "KIFMEC specific purpose company" which has been established in order to lease a hospital building to Kobe International Frontier Medical Center ("KIFMEC"). more info >>
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Yokogawa Electric announced that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). more info >>
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
ACN Newswire
 Press Release News

U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures (Oct 21, 2014)
Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for its in-house developed antiepileptic drug Fycompa for the treatment of primary generalized tonic-clonic seizures (PGTC), a severe form of seizures, in patients 12 years or older. more info >>
NEC Technology Alleviates the Stress of Taking Blood Pressure (Oct 15, 2014)
NEC Corporation has developed a first-of-its-kind(1) blood pressure measurement technology that enables high-precision blood pressure measurements with a low application of pressure (stress). more info >>
U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib (Oct 15, 2014)
Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) submitted by its U.S. subsidiary Eisai Inc. for its novel in-house developed anticancer agent lenvatinib mesylate as a treatment for progressive radioiodine-refractory differentiated thyroid cancer and granted the NDA Priority Review status.
more info >>

U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome (Oct 15, 2014)
Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's antiepileptic agent BANZEL, which was approved in November 2008 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years older and adults. more info >>
U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and Vomiting (CINV) (Oct 14, 2014)
World's First Oral Fixed Combination Targeting Two Critical Pathways Involved in CINV Eisai Co., Ltd. announced today that Helsinn Healthcare S.A. has received approval from the U.S. Food and Drug Administration (FDA) for AKYNZEO, indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including but not limited to highly emetogenic chemotherapy, in the U.S. more info >>
 Global Press Release

U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures (Oct 21, 2014)

NEC Technology Alleviates the Stress of Taking Blood Pressure (Oct 15, 2014)

U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib (Oct 15, 2014)

U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome (Oct 15, 2014)

U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and Vomiting (CINV) (Oct 14, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)